Cracking the Code: Mayo Clinic Hosts First U.S. “Undiagnosed Hackathon” to Solve Rare Medical Mysteries

On Sunday, more than 100 medical experts from across the globe gathered in Rochester for the Mayo Clinic’s four-day “Undiagnosed Hackathon”—a pioneering event dedicated to solving rare diseases that have…

Continue Reading Cracking the Code: Mayo Clinic Hosts First U.S. “Undiagnosed Hackathon” to Solve Rare Medical Mysteries

A Breakthrough in Avacopan Measurement: New LC-MS/MS Method Enables Precision Monitoring in Vasculitis Patient

Avacopan, a novel oral therapy for antineutrophil cytoplasmic antibody-associated vasculitis (ANCA-AAV), has changed treatment paradigms for this rare but serious disease. However, until now, a validated technique for measuring avacopan…

Continue Reading A Breakthrough in Avacopan Measurement: New LC-MS/MS Method Enables Precision Monitoring in Vasculitis Patient

The Impact of Pharmacy Benefit Managers and Most Favored Nation Policy on Biosimilar Adoption and Healthcare Costs

Editor's Note: This article is an opinion piece shared with Patient Worthy from our partner network. Opinion pieces may not reflect the views of Patient Worthy, its employees, or any…

Continue Reading The Impact of Pharmacy Benefit Managers and Most Favored Nation Policy on Biosimilar Adoption and Healthcare Costs

FDA Reviewing First-Ever Treatment for Barth Syndrome, Possibly Marking Major Milestone for Rare Disease Community

The U.S. Food and Drug Administration (FDA) is reviewing the first medication specifically developed for Barth syndrome, a rare and life-threatening genetic disorder. As reported by STAT, this medication could…

Continue Reading FDA Reviewing First-Ever Treatment for Barth Syndrome, Possibly Marking Major Milestone for Rare Disease Community